219 related articles for article (PubMed ID: 34543563)
1. Failure of Biologic Therapy in Psoriasis.
Cardona R; Pelet Del Toro NM; Michelen-Gómez E; Arias-Berrios GE; Martín-García RF
P R Health Sci J; 2021 Jun; 40(2):63-67. PubMed ID: 34543563
[TBL] [Abstract][Full Text] [Related]
2. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
[TBL] [Abstract][Full Text] [Related]
3. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
4. First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Assan F; Tubach F; Arlegui H; Viguier M; Beylot-Barry M; Dupuy A; Beneton N; Joly P; Jullien D; Mahé E; Paul C; Richard MA; Bachelez H; Giboin C; Chosidow O; Sbidian E;
Dermatology; 2021; 237(3):338-346. PubMed ID: 33535213
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
6. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.
Roche H; Bouiller K; Puzenat E; Deveza E; Roche B; Pelletier F; van de Laak A; Dupond AS; Nardin C; Aubin F
J Dermatolog Treat; 2019 Sep; 30(6):540-544. PubMed ID: 29848153
[No Abstract] [Full Text] [Related]
8. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
9. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.
Verma L; Mayba JN; Gooderham MJ; Verma A; Papp KA
J Cutan Med Surg; 2018; 22(1):38-43. PubMed ID: 29056080
[TBL] [Abstract][Full Text] [Related]
10. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
11. Switching biologics in children with psoriasis: Results from the BiPe cohort.
Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
[TBL] [Abstract][Full Text] [Related]
13. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
[TBL] [Abstract][Full Text] [Related]
14. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
15. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
16. Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.
Tokuyama M; Ota M; Saitoh R; Sawamura M; Okitsu N; Shimizu T; Kondoh A; Yamaoka H; Mabuchi T
Tokai J Exp Clin Med; 2020 Dec; 45(4):230-235. PubMed ID: 33300595
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
[TBL] [Abstract][Full Text] [Related]
18. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
[TBL] [Abstract][Full Text] [Related]
19. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
[TBL] [Abstract][Full Text] [Related]
20. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
